Biogen Reports Phase 2 SYNERGY Results for Opicinumab in Multiple Sclerosis

Biogen today announced results from the Phase 2 SYNERGY trial evaluating opicinumab in patients with relapsing multiple sclerosis. The trial evaluated opicinumab as an add-on to interferon beta-1a for promoting remyelination. While the trial did not meet its primary endpoint in the overall population, exploratory analyses suggested potential benefit in specific patient subgroups, informing future development strategies.